Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Pharmaceuticals

    Pharmaceuticals - Page 71

    Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

    Tests indicate heartburn drug Zantac does not form carcinogen in users: USFDA

    Medical Dialogues Bureau2 Nov 2019 9:30 AM IST
    Zantac sold over-the-counter in the United States by French drugmaker Sanofi SA, and some of its generic versions, have been recalled due to possible...
    Revenue from operations stood at Rs 2005 crore in Q2: Torrent Pharma

    Revenue from operations stood at Rs 2005 crore in Q2: Torrent Pharma

    Medical Dialogues Bureau2 Nov 2019 9:15 AM IST
    Consolidated revenue from operations stood at Rs 2,005 crore for the quarter under consideration as against Rs 1,894 crore for the same period last...
    Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

    Mirati Therapeutics oral drug MRTX849 shrinks tumours in early-stage trial

    Medical Dialogues Bureau2 Nov 2019 9:00 AM IST
    Out of 17 patients enrolled in the Phase 1 trial of Mirati Therapeutics' oral drug MRTX849, 12 have been evaluated, including six with lung cancer and...
    GSK Pharma reports Q2 profit at Rs 503 crore

    GSK Pharma reports Q2 profit at Rs 503 crore

    Medical Dialogues Bureau1 Nov 2019 9:15 AM IST
    GSK Pharmaceuticals continues to drive improved operational efficiencies reflecting in earnings before interest, tax, depreciation and amortisation...
    Bayer Roundup suits increase to 42700

    Bayer Roundup suits increase to 42700

    Medical Dialogues Bureau1 Nov 2019 9:00 AM IST
    A court-appointed mediator between Bayer and US plaintiffs in August denied reports the company had offered an $8 billion settlement to get the cases...
    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Merck loses bid to revive over Rs 18 crore patent verdict against Gilead

    Farhat Nasim31 Oct 2019 3:27 PM IST
    In 2016, a jury returned a verdict that Gilead Science's hepatitis C drugs Sovaldi and Harvoni infringed the patent, which Merck acquired when it...
    JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

    JnJ enters series of new collaborations with Government, NGOs for ending TB in India by 2025

    Farhat Nasim31 Oct 2019 12:39 PM IST
    Hyderabad: Johnson & Johnson(JnJ) recently announced the expansion of its tuberculosis (TB) program in India in advance of the 50th Union World...
    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    SETBACK: Novartis Zolgensma study halted by USFDA amid safety concerns

    Medical Dialogues Bureau31 Oct 2019 9:45 AM IST
    Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings...
    Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

    Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

    Medical Dialogues Bureau31 Oct 2019 9:25 AM IST
    The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous...
    GSK lifts annual profit forecast after third quarter beat on vaccines strength

    GSK lifts annual profit forecast after third quarter beat on vaccines strength

    Medical Dialogues Bureau31 Oct 2019 9:00 AM IST
    GSK now expects full-year profit to be roughly flat compared to last year at constant currency, up from a previous forecast of a fall of 3% to 5%.New...
    AstraZeneca sells European rights for schizophrenia drug Seroquel, Seroquel XR for USD 178 million

    AstraZeneca sells European rights for schizophrenia drug Seroquel, Seroquel XR for USD 178 million

    Farhat Nasim30 Oct 2019 5:25 PM IST
    The treatment, Seroquel, and another version, Seroquel XR, have lost patent protection in Europe and Russia, AstraZeneca said. The drug variants are...
    IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

    IOL Chemicals and Pharma Ibuprofen manufacturing facilities in Barnala clears USFDA inspection

    Medical Dialogues Bureau30 Oct 2019 2:11 PM IST
    Mumbai: IOL Chemicals and Pharmaceuticals (IOLCP) recently received a communication from US Food and Drug Administration (USFDA) with respect to an...
    PrevNext

    Popular Stories

    Protect Your Loved Ones with a Term Plan that’s Smart

    Protect Your Loved Ones with a Term Plan that’s Smart

    Paras Healthcare ties up with J K Hospital, plans Rs 50 crore investment for comprehensive services

    Paras Healthcare ties up with J K Hospital, plans Rs 50 crore investment for comprehensive services

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Religare Enterprises to divest stake in arm to Kedaara for Rs 200 crore

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    Mediclaim cannot be denied on presumption of pre-existing disease: NCDRC

    No discussion on alleged bribes given by pharma firms to doctors at PM Modis meet, claims IPA

    No discussion on alleged bribes given by pharma firms to doctors at PM Modi's meet, claims IPA

    MEDICREA UNiD IB3D Patient-Matched interbody cages get USFDA clearance

    MEDICREA UNiD IB3D Patient-Matched interbody cages get USFDA clearance

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Coronavirus: CDSCO issues guidelines to be followed while visiting CDSCO office.

    Ministry of AYUSH invites initial bids for strategic sale of IMPCL

    Ministry of AYUSH invites initial bids for strategic sale of IMPCL

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok